Chemoprevention for keratinocytic (pre)cancers: Balancing the risks and benefits

Archives of Dermatology

Volumn 148, Issue 5, 2012, Pages 638-640

  Hollestein, Loes M ^a   Koomen, Els R ^b   Nijsten, Tamar ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; SUNSCREEN;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME INDUCTION; HISTOPATHOLOGY; HUMAN; KERATINOCYTIC CANCER; LOW DRUG DOSE; MELANOMA; NON MELANOMA SKIN CANCER; NONHUMAN; NOTE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN CANCER; SQUAMOUS CELL CARCINOMA; UNITED STATES;

EID: 84861368217     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2797     Document Type: Note

References (10)

1. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010;102(24):1835-1844.
2. Rundhaug JE, Fischer SM. Cyclo-oxygenase-2 plays a critical role in UVinduced skin carcinogenesis. Photochem Photobiol. 2008;84(2):322-329. (Pubitemid 351424030)
3. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, SternRS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011;131(7):1460-1468.
4. Tang JY, Aszterbaum M, Athar M, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila). 2010;3(1):25-34.
5. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal antiinflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol. 2005;53(6):966-972. (Pubitemid 41677321)
6. Bath-Hextall F, Leonardi-Bee J, Somchand N, Webster A, Delitt J, Perkins W. Interventions for preventing non-melanoma skin cancers in high-risk groups. Cochrane Database Syst Rev. 2007;(4):CD005414.
7. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795-797. (Pubitemid 18094914)
8. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.
9. Bresalier RS, Sandler RS, Quan H, et al Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352 (11):1092-1102. (Pubitemid 40365350)
10. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.